Patrick Williams: Matt, I think that’s a really key point that Tom about — because now we’ve gotten maybe three or four questions on pricing. And as Tom said, and I’ll just repeat it so, that everyone hears it, pricing is a component. But if you go back and think about what we’ve talked about since early January during our initial pre-announcement, we talked about the importance of increasing surgeon confidence. We’ve talked about these papers that are going to come out to help that. In Tom’s prepared remarks, he talked about the new department that we created. All of this is focused on increasing surgeon confidence to make our procedure, not only more predictable, but more efficient for them. And that ultimately will result in what Tom, did a little bit of a staple that the meeting is at where they’re going to move down the diopter curve. And so that’s what gives us the confidence not only this year, but as we move forward to our Vision 2026.
Matthew O’Brien: Okay. Appreciate that. And then just rest of the world or I guess China plus rest of the world, you just came off a really good Q4. And I’m looking at the 10% number for China and then kind of flat for the rest of the world. Can you talk a little bit about some of the puts and takes in there? Because it seems pretty conservative in terms of your view on the OUS business. I’m not – again, I’m not sure what you’re really factoring in from an economic perspective in China or just other parts of the world, but would just love to hear some of the things you are contemplating. And then how conservative that outlook is specifically? Thank you.
Tom Frinzi: Yes. Thanks, Matt. Again, you’re using the word conservative. I think I’ll use the word prudent. I think look at — there’s still uncertainty out in the world, macro headwinds. And I think certainly we’ve said not only China, but the US would grow at 10% and all the other markets would be relatively flat. But again, we’re contemplating another year of growth outpacing the refractive growth around the world. Most markets are down to flat at best, and we’re going to continue to grow even in flat markets. So, I think too early to tell. We feel good about the start of the year and I would just encourage you to stay tuned and we’ll keep you all posted.
Operator: Thank you. And our next question today comes from David Saxon with Needham. Please go ahead.
Q – Unidentified Analyst: Hi, guys. This is Joseph [ph] on for David. Maybe just looking at 2024, we’re just kind of curious how meaningful if at all the STELLA ordering platform the launch is going to be to 2024 especially in the back half. Does it make it easier for STAAR to fulfill the orders? Or is it more about the improving user interface? And I guess also, if we could just — maybe just get an update on that call center program. How has that been going? Has it been driving volumes anything noticeable? Answer
Tom Frinzi: Yes. Thank you, Joseph for the question. Look STELLA, I think is all about operation efficiency within a practice. Is it going to drive meaningful growth to the US business? Probably, not. But it certainly is going to make our customers more efficient and we think out of that comes a real positive. So it’s more about operation efficiency. It did improve GUI, so it will be easier for them to place their orders et cetera. So in the end of the day, we think that’s very, very positive. In terms of the second part of your question, if you’ll repeat that for me?
Unidentified Analyst: Yeah. Just the update on the call center program?
Tom Frinzi: Yeah. SeaLytics [ph] continues to be a test for us. We’re about 4.5, five months into when we brought it wider in November. We like what we’re seeing. I think it’s still too early to tell, we’re generating good information as I’ve previously stated about how patients find us, what physicians are being sought after et cetera, et cetera. We’re generating probably about three really strong qualified leads a day. But we’re still watching it. We’re still learning and we’ll keep you positive — updated as we have positive news moving forward.
Operator: Thank you. And our next question today comes from Steve Lichtman with Oppenheimer. Please go ahead.
Steve Lichtman: Thank you. Good evening, guys. Tom based on your estimates, what was overall refractive market growth in the US and worldwide in 2023? And what does your outlook for 2024 assume in terms of that growth in the US and worldwide?
Tom Frinzi: Yeah. Appreciate that Steve. I think in the US, it wasn’t about growth. It was a real deceleration. I think in the fourth quarter, the market research isn’t out yet but it would suggest that it was about 20% down in many of the US practices in the fourth quarter. And that’s after up through the first three quarters anywhere from 9% to 15% down. So market was significantly down and us being up 14%, 15% in the US again outpacing that market. I’d say around the world places like China in 2023 you saw a nice first half growth and then a deceleration in the second half that brought it back down to mid-single-digit growth overall. And we think it’s going to be a slow ramp-up in the first half of China in 2024 and maybe get back to mid single digits to 10% in the back half of the year.
So I think the trend is continuing to be a deceleration of refractive procedures, which in a certain way is just the inverse for us because we continue to outpace the market. And I think people are recognizing that EVO ICL is not only better medicine by the outcomes that we’re producing, but it can be better business. And more and more practices around the world are embracing lens-based refractive surgery.
Steve Lichtman: Thanks, Tom. Patrick just in terms of, sort of, where investments are in the P&L, it looks like sales and marketing will be up maybe just a little bit year-over-year, but we’ll see a step-up on the G&A side. So again can you talk about what that G&A investment is in any more detail?
